Epidemiology and treatment of acute promyelocytic leukemia in Latin America

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages

  Rego, Eduardo Magalhães ^a   Jácomo, Rafael Henriques ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84923646294     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.049     Document Type: Review

References (36)

1. Pombo-de-Oliveira MS, Carvalho SM, Borducchi D, Dobbin J, Salvador J, Correa RB, Moellman A, Loureiro P, Chiattone C, Rios M. Adult T-cell leukemia/lymphoma and cluster of HTLV-I associated diseases in Brazilian settings. Leuk Lymphoma. 2001;42:135-144. http://dx.doi.org/10.3109/10428190109097685
2. Pombo De Oliveira MS, Loureiro P, Bittencourt A, Chiattone C, Borducchi D, De Carvalho SM, Barbosa HS, Rios M, Sill A, Cleghorn F, Blattner W. Geographic diversity of adult t-cell leukemia/lymphoma in Brazil. The Brazilian ATLL Study Group. Int J Cancer. 1999;83:291-298. http://dx.doi.org/10.1002/(SICI)1097-0215(19991029)83:3291::AID-IJC13.0.CO;2-P
3. Gupta S, Bonilla M, Fuentes SL, Caniza M, Howard SC, Barr R, Greenberg ML, Ribeiro R, Sung L. Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. Br J Cancer. 2009;100:1026-1031. http://dx.doi.org/10.1038/sj.bjc.6604895 PMid:19293804 PMCid:2669993
4. de Souza Reis R, de Camargo B, de Oliveira Santos M, de Oliveira JM, Azevedo Silva F, Pombo-de-Oliveira MS. Childhood leukemia incidence in Brazil according to different geographical regions. Pediatr Blood Cancer. 2011;56:58-64. http://dx.doi.org/10.1002/pbc.22736
5. Ruiz-Arguelles GJ, Garces-Eisele J, Reyes-Nunez V, Gomez-Rangel JD, Ruiz-Delgado GJ. More on geographic hematology: the breakpoint cluster regions of the PML/RARalpha fusion gene in Mexican Mestizo patients with promyelocytic leukemia are different from those in Caucasians. Leuk Lymphoma. 2004;45:1365-1368. http://dx.doi.org/10.1080/10428190310001657344
6. Jácomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, Bittencourt HN, Bittencourt RI, Bortolheiro TC, Paton EJ, Bendlin R, Ismael S, Chauffaille Mde L, Silva D, Pagnano KB, Ribeiro R, Rego EM. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92:1431-1432. http://dx.doi.org/10.3324/haematol.10874 PMid:18024380
7. Douer D. The epidemiology of acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:357-367. http://dx.doi.org/10.1016/S1521-6926(03)00065-3
8. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996;88:1390-1398. PMid:8695858
9. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. EMBO J. 1992;11:1397-1407. PMid:1314166 PMCid:556589
10. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111:3395-3402. http://dx.doi.org/10.1182/blood-2007-07-100669 PMid:18195095
11. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996;87:308-313. PMid:8547657
12. Ruiz-Argüelles, G.J. (1997) Promyelocytic leukaemia in Mexican mestizos [letter]. Blood, 89, 348-349. PMid:8978313
13. Melo RA, de Vasconcellos JF, Melo FC, Machado CG, Lacerda TM, Souto FR. PML-RARalpha fusion gene transcripts and biological features in acute promyelocytic leukemia patients. Clin Lab Haematol. 2006;28:126-129. http://dx.doi.org/10.1111/j.1365-2257.2006.00763.x PMid:16630218
14. De Salvo L, Weir Medina J, Gómez Sánchez O, de Baena ES, de Ramos BU, Guevara J, Luengo Vera J, de Vizcaíno MA, Sánchez H, de León E. [Acute promyelocytic leukemia in the west of Venezuela]. Sangre (Barc). 1989;34:329-331.
15. Otero JC, Santillana S, Fereyros G. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996;88:377-377.
16. Mendes WL, Coser VM, Ramos G, Pereira W, Lopes LF, de Oliveira MS. The apparent excess of acute promyelocytic leukemia in infant acute leukemias in Brazil. Haematologica. 2004;89:ELT16-ELT16. PMid:15533849
17. Sierra M, Alonso A, Odero MD, Gonzalez MB, Lahortiga I, Perez JJ, Garcia JL, Gutierrez NC, Calasanz MJ, San Miguel JF, Hernandez JM. Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain. Leuk Res. 2006;30:943-948. http://dx.doi.org/10.1016/j.leukres.2005.12.025 PMid:16503352
18. Tomas JF, Fernandez-Ranada JM. About the increased frequency of acute promyelocytic leukemia among Latinos: the experience from a center in Spain. Blood. 1996;88:2357-2358. PMid:8822960
19. Pulsoni A, Stazi A, Cotichini R, Allione B, Cerri R, Di Bona E, Nosari AM, Pagano L, Recchia A, Ribersani M, Rocchi L, Veneri D, Visani G, Mandelli F, Mele A. Acute promyelocytic leukaemia: epidemiology and risk factors. A report of the GIMEMA Italian archive of adult acute leukaemia. GIMEMA Cooperative Group. Eur J Haematol. 1998;61:327-332. http://dx.doi.org/10.1111/j.1600-0609.1998.tb01096.x
20. Moorman AV, Roman E, Cartwright RA, Morgan GJ. Patients entered into MRC AML trials are biologically representative of the totality of the disease in the UK. Clin Lab Haematol. 2002;24:263-265. http://dx.doi.org/10.1046/j.1365-2257.2002.00445.x PMid:12181033
21. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, Rangert Derolf A, Stockelberg D, Tidefelt U, Wahlin A, Wennström L, Höglund M, Juliusson G. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128-1134. http://dx.doi.org/10.1038/leu.2011.78 PMid:21502956
22. Rego EMR. Development of the IC APL Project in Brazil. Haematologica Reports. 2005;1:93-95.
23. Sanz MA, Lo CF, Martin G, Avvisati G, Rayon C, Barbui T, az-Mediavilla J, Fioritoni G, Gonzalez JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-1253. PMid:10942364
24. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997;90:1656-1663. PMid:9269786
25. Douer D, Santillana S, Ramezani L, Samanez C, Slovak ML, Lee MS, Watkins K, Williams T, Vallejos C. Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene. Br J Haematol. 2003;122:563-570. http://dx.doi.org/10.1046/j.1365-2141.2003.04480.x PMid:12899711
26. Dong S, Geng JP, Tong JH, Wu Y, Cai JR, Sun GL, Chen SR, Wang ZY, Larsen CJ, Berger R. Breakpoint clusters of the PML gene in acute promyelocytic leukemia: primary structure of the reciprocal products of the PML-RARA gene in a patient with t(15;17). Genes Chromosomes Cancer. 1993;6:133-139. http://dx.doi.org/10.1002/gcc.2870060302
27. Uriarte MA, Zubillaga MNZ, Chacon AC, Bononi RB, Lombardi VL, Giordano HG, Fernandez IF, Manrique GM, Di Matteo CM, Pavlovsky SP, Martinez LM. Genetic Characterization and Follow-up of MRD in Acute Promyelocytic Leukemia Patients from Argentina and Uruguay. Haematologica Reports. 2005;1:47.
28. da Costa Moraes CA, Trompieri NM, Cavalcante Felix FH. Pediatric acute promyelocytic leukemia: all-transretinoic acid therapy in a Brazilian pediatric hospital. J Pediatr Hematol Oncol. 2008;30:387-390. http://dx.doi.org/10.1097/MPH.0b013e3181662493 PMid:18458575
29. Pagnano KB, de Carvalho Duarte G, Lorand-Metze I, Delamain MT, Miranda EC, De Souza CA. Treatment outcome of acute promyelocytic leukemia with modified aida protocol. Adv Hematol. 2010;2010:672137.
30. Leander C, Fu LC, Peña A, Howard SC, Rodriguez-Galindo C, Wilimas JA, Ribeiro RC, Haik B. Impact of an education program on late diagnosis of retinoblastoma in Honduras. Pediatr Blood Cancer. 2007;49:817-819. http://dx.doi.org/10.1002/pbc.21052
31. Howard SC, Pedrosa M, Lins M, Pedrosa A, Pui CH, Ribeiro RC, Pedrosa F. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA. 2004;291:2471-2475. http://dx.doi.org/10.1001/jama.291.20.2471 PMid:15161898
32. Howard SC, Marinoni M, Castillo L, Bonilla M, Tognoni G, Luna-Fineman S, Antillon F, Valsecchi MG, Pui CH, Ribeiro RC, Sala A, Barr RD, Masera G, MISPHO Consortium Writing Committee. Improving outcomes for children with cancer in lowincome countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-Part I. Pediatr Blood Cancer. 2007;48:364-369. http://dx.doi.org/10.1002/pbc.21003
33. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, Pasqualucci L, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, Pelicci PG, Pileri S. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood. 1997;90:4046-4053. PMid:9354674
34. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875-1891. http://dx.doi.org/10.1182/blood-2008-04-150250 PMid:18812465
35. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B, PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115:5137-5146. http://dx.doi.org/10.1182/blood-2010-01-266007 PMid:20393132
36. Rego EM, Kim HT, Ruiz-Arguelles GJ, Uriarte R, Jacomo RH, Gutiérrez-Aguirre H, Melo RAM, Bittencourt R, Pasquini R, Pagnano KBB, Fagundes EM, Chauffaille MLLF, Chiattone C, Martinez L, Gomez-Almaguer D, Kwaan HC, Garcez-Eisele J, Gallagher RE, Niemeyer CM, Lowenberg B, Ribeiro RC, Lo-Coco F, Sanz MA. Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group. Blood (ASH Annual Meeting Abstracts). 2009;3.